The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market has seen significant growth lately. The market is projected to increase from $2.00 billion in 2024 to $2.60 billion in 2025, translating to a compound annual growth rate (CAGR) of 30.0%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry?
The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market is expected to expand to a size of $7.38 billion by 2029, developing at a compound annual growth rate (CAGR) of 29.8%.
Download Your Free Sample of the 2025 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The key drivers in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are:
•Rise in obesity and obesity-related diseases prevalence
•Progress in early intervention procedures
•Expansion of reimbursement mechanisms and insurance coverage
•Growing awareness of liver diseases
Global Market Segmentation: Identifying Major Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry Segments
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Pre-order the 2025 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The key trends in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are:
•An increase in technological advancements is expected to shape the MASH treatment market.
•There is a growing trend towards the development of robust pipelines for MASH treatment.
•Strategic collaborations and partnerships are emerging as a significant trend in MASH treatment market.
•Personalized medicine and precision therapeutics are gaining momentum in the MASH treatment market.
Who Are the Top Competitors & Leading Players in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Major players in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Sanofi SA
• AstraZeneca PLC
• Novartis AG
• Eli Lily and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Apollo Health and Lifestyle Limited
• Jenny Craig
• Celerion
• Nutrisystem
• Madrigal Pharmaceuticals
• Anoos Clinic
• 89 Bio
• Biosynth
• DiogenX
• Galectin Therapeutics Inc.
• Galmed Pharmaceuticals
• Hepion Pharmaceuticals
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024
